Domperidone is NOT appropriate for treating anorexia (loss of appetite) as a primary indication
Domperidone should not be used as first-line treatment for anorexia, and its use is specifically limited to gastroparesis-related symptoms (nausea, vomiting, early satiety) in carefully selected patients with significant monitoring requirements. 1
Evidence-Based Rationale
Primary Indication: Gastroparesis, Not Anorexia
The 2025 AGA guidelines explicitly state that domperidone is suggested against as first-line treatment even for gastroparesis, with only conditional recommendation based on very low-quality evidence 1. The drug may help with:
- Nausea and vomiting
- Early satiety
- Bloating
However, loss of appetite (anorexia) is not a primary indication for domperidone use.
When Domperidone Might Be Considered (Gastroparesis Context Only)
Domperidone may be appropriate only in highly specific scenarios 1:
- Patients with gastroparesis who experienced neurologic adverse effects from metoclopramide
- Patients with movement disorders (e.g., Parkinson's disease) who cannot tolerate metoclopramide
- Patients declining metoclopramide due to safety concerns
Critical caveat: Even in these scenarios, the patient must have gastroparesis with documented delayed gastric emptying, not simple anorexia.
Regulatory and Safety Barriers
FDA Status
Domperidone is NOT FDA-approved for human use in the United States 1, 2. Prescription requires:
- Expanded access investigational new drug (IND) application
- The current U.S. supplier is exiting the market, making access extremely limited 1
Mandatory Pre-Treatment Requirements 1
Before initiating domperidone (if available):
- Baseline ECG - measure QTc interval
- Serum potassium level
- Serum magnesium level
Ongoing Monitoring Protocol 1
- Assess efficacy at 4-8 weeks to determine continuation
- Monitor throughout treatment:
- Serum potassium
- Serum magnesium
- ECG QTc interval
Cardiovascular Risks
Domperidone carries significant cardiac safety concerns 3:
- QT prolongation
- Ventricular tachycardia risk
- Contraindicated in patients with cardiac comorbidities
- Should avoid doses >30 mg/day per European guidelines
Alternative Approaches for Anorexia
For Anorexia Nervosa (Eating Disorder)
The 2023 APA guidelines make no recommendation for domperidone in anorexia nervosa 4. Treatment focuses on:
- Eating disorder-focused psychotherapy (adults)
- Family-based treatment (adolescents/emerging adults)
- Weight restoration through nutritional rehabilitation
For Cancer-Related Anorexia
The 2023 ASCO guidelines recommend 5:
- Low-dose olanzapine (2.5-5 mg once daily) - improves appetite and weight gain
- Short-term progesterone analogs or corticosteroids as alternatives
- No mention of domperidone for cancer cachexia
For General Appetite Stimulation
The 2003 FNCLCC guidelines on appetite stimulants in oncology 6:
- Corticosteroids and synthetic progestogens have demonstrated appetite-stimulating effects
- Domperidone is not included as a recommended appetite stimulant
Clinical Bottom Line
Do not prescribe domperidone for anorexia. The drug:
- Lacks FDA approval for any human indication in the U.S.
- Has no evidence base for treating anorexia as a primary condition
- Carries significant cardiac risks requiring intensive monitoring
- Is increasingly unavailable in the United States
- Has superior alternatives for appetite stimulation (olanzapine, corticosteroids, progestogens)
If a patient has both anorexia AND documented gastroparesis with failed metoclopramide therapy, domperidone might be considered through FDA IND application, but only with comprehensive cardiac monitoring and after exhausting other options. The limited long-term data showing 36% of patients continuing treatment at 7.6 years 7 applies only to gastroparesis symptoms, not anorexia treatment.